Hints and tips:
Related Special Reports
...about vaccines and 60 per cent about the pandemic were found to be misleading....
...Shares in GSK have fallen 5 per cent in the past five years, while many of its European rivals including Novo Nordisk, AstraZeneca and Novartis have soared....
...Shares in Pfizer, which developed a vaccine and an antiviral drug, have plummeted 46 per cent from their peak in late 2021, while its German vaccine partner BioNTech is down 75 per cent and rival Moderna...
...Beset with production issues, Novavax was late to market, although its Covid vaccine, made with a more traditional technology, has been shown to be safe and highly effective in trials....
...Pfizer generated $37.8bn in sales from the vaccine in 2022 and BioNTech €17bn. The vaccines were the first to use mRNA technology....
...A top-five shareholder in struggling Covid-19 vaccine maker Novavax is calling for an “urgent shake-up” of the board and an overhaul of its sales strategy, as the stock is down 99 per cent from its pandemic...
...It has also announced acquisitions of Chinese oncology company Gracell for $1bn and vaccine maker Icosavax for $1.1bn in December. Shares in AstraZeneca dipped 1.1 per cent in morning trading....
...Their aim was to improve global co-operation on alert systems, data sharing and research, as well as the production and distribution of health “countermeasures”, such as vaccines, medicines, diagnostics...
...Mentioned in this podcast: Tesla shareholders braced for worst results in 7 years Why oil prices remain steady even as Middle East tensions escalate Covid vaccine makers to clash in London over mRNA patent...
...J&J’s medtech division has outstripped the growth of the company’s drugs and diagnostics business, generating $30.4bn in sales last year, or 35 per cent of group revenues....
...Novartis said in a statement on Friday it was “confident that the spin-off is in the best interests of shareholders, creating a European champion and a global leader in generics and biosimilars, and a more...
...Vaccines received $11.3bn, compared with $6.2bn for therapeutics research and $1.3bn for diagnostics research....
...A group of Wall Street traders maliciously drove down the share price of a Maryland biotech with a promising new brain cancer vaccine, in pursuit of the marginal profits to be made by buying the stock cheaply...
...Merck and Novartis signing smaller deals on Monday....
...Pharmaceuticals groups Pfizer and Moderna, which have both faced criticism from fringe groups over their Covid-19 vaccines, also spent heavily on security for their CEOs last year....
...Pfizer cut its full-year guidance for revenues from the Covid vaccine by about $2bn and announced inventory write-offs and other charges of $900mn....
...“I began to change my mind around 2020 with the new mRNA vaccines and computational biology,” Cowen tells me. “Then AI came along....
...Prashant Yadav is a senior fellow at the Center for Global Development and affiliate professor at Insead Many groundbreaking innovations in life sciences — from novel treatments and diagnostics to digital...
...“By 2020 UK vaccine manufacturing had almost gone . . . while we didn’t have a diagnostics industry on any scale, which made it very hard to scale up testing.”...
...Eric Topol, a cardiologist who co-authored a paper on the condition in Nature Reviews Microbiology, says diagnostics are important for creating treatments, as they allow recovery to be measured....
...Pharmaceutical products such as medicines, vaccines and diagnostics can be protected by several types of intellectual property, including patents and trade secrets....
...There’s no commercial market really for TB drugs, diagnostics or vaccines.” Thomas Breuer, head of global health at GSK, agreed....
...After raking in billions of dollars through sales of the Covid vaccine it co-developed with Germany’s BioNTech during the pandemic and seeing share prices surge, Pfizer has struggled to reorientate its pipeline...
...Revenue for Pfizer’s Comirnaty vaccine and Paxlovid, an oral treatment, are expected to generate just $8bn in 2024. That compares with $57bn in 2022 and a forecast of $12.5bn for 2023....
...Crisis at Hargreaves Lansdown In November 2020, a frenzy of trading among retail investors rushed to cash in on a sharp market rally triggered by positive Covid-19 vaccine news....
International Edition